Inflammation unites diverse acute and chronic diseases
Peter Libby,Robin Smith,Eric J. Rubin,Marilyn K. Glassberg,Michael E. Farkouh,Robert S. Rosenson
DOI: https://doi.org/10.1111/eci.14280
2024-07-26
European Journal of Clinical Investigation
Abstract:A depiction of a generic chronic inflammatory disease. On the left, T lymphocytes of various functional subtypes, effectors of adaptive immunity, send messages to mononuclear phagocytes, innate immune cells. The T lymphocytes elaborate mediators including cytokines and chemokines that direct the behavior of not only the mononuclear phagocytes, but also cells intrinsic to the inflamed tissue, shown in the middle. In general, these cells include epithelial cells and mesenchymal cells of different types, depending on the organ or tissue. These immune mediators elicit a relatively stereotyped set of functions: proliferation, fibrosis, remodeling of the extracellular matrix (ECM), recruitment of white blood cells (WBC), augmenting oxidative stress, and spurring the creation or growth of new microvessels: angiogenesis. The column on the left lists the types of epithelial cells and the column on the right lists some mesenchymal cells implicated in diseases of various tissues. In blood vessels, the endothelial cell and smooth muscle cell contribute to diseases. In the gastrointestinal system, the enterocyte. In the kidney, glomerular endothelial cells (EC) and mesangial cells. In the synovium, synovial epithelial cells and synoviocytes. In the lung, bronchial epithelial cells and bronchoalveolar cells. The disease icons on the bottom indicate how shared pathophysiologic mechanisms often spurred and regulated by inflammation may give rise to diverse diseases, traditionally considered in isolation. Background Inflammation and immunity contribute pivotally to diverse acute and chronic diseases. Inflammatory pathways have become increasingly targets for therapy. Yet, despite substantial similarity in mechanisms and pathways, the scientific, medical, pharma and biotechnology sectors have generally focused programs finely on a single disease entity or organ system. This insularity may impede progress in innovation and the harnessing of powerful new insights into inflammation biology ripe for clinical translation. Methods A multidisciplinary thinktank reviewed highlights how inflammation contributes to diverse diseases, disturbed homeostasis, ageing and impaired healthspan. We explored how common inflammatory and immune mechanisms that operate in key conditions in their respective domains. This consensus review highlights the high degree of commonality of inflammatory mechanisms in a diverse array of conditions that together contribute a major part of the global burden of morbidity and mortality and present an enormous challenge to public health and drain on resources. Results We demonstrate how that shared inflammatory mechanisms unite many seemingly disparate diseases, both acute and chronic. The examples of infection, cardiovascular conditions, pulmonary diseases, rheumatological disorders, dementia, cancer and ageing illustrate the overlapping pathogenesis. We outline opportunities to synergize, reduce duplication and consolidate efforts of the clinical, research and pharmaceutical communities. Enhanced recognition of these commonalties should promote cross‐fertilization and hasten progress in this rapidly moving domain. Conclusions Greater appreciation of the shared mechanisms should simplify understanding seemingly disparate diseases for clinicians and help them to recognize inflammation as a therapeutic target which the development of novel therapies is rendering actionable.
medicine, general & internal, research & experimental